Payden & Rygel Reduces Stock Holdings in Eli Lilly and Company $LLY

Payden & Rygel lowered its holdings in Eli Lilly and Company (NYSE:LLY) by 80.2% during the third quarter, Holdings Channel reports. The fund owned 3,120 shares of the company’s stock after selling 12,600 shares during the quarter. Payden & Rygel’s holdings in Eli Lilly and Company were worth $2,381,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in LLY. Clearstead Trust LLC boosted its holdings in Eli Lilly and Company by 38.4% in the third quarter. Clearstead Trust LLC now owns 6,726 shares of the company’s stock valued at $5,132,000 after purchasing an additional 1,866 shares during the last quarter. Avalon Trust Co raised its stake in shares of Eli Lilly and Company by 9.6% during the 3rd quarter. Avalon Trust Co now owns 966 shares of the company’s stock valued at $737,000 after buying an additional 85 shares during the last quarter. Kovitz Investment Group Partners LLC lifted its holdings in shares of Eli Lilly and Company by 7.8% in the 3rd quarter. Kovitz Investment Group Partners LLC now owns 71,907 shares of the company’s stock valued at $54,865,000 after buying an additional 5,192 shares during the period. Alteri Wealth LLC boosted its stake in shares of Eli Lilly and Company by 5.2% in the third quarter. Alteri Wealth LLC now owns 3,150 shares of the company’s stock worth $2,404,000 after buying an additional 156 shares during the last quarter. Finally, Koshinski Asset Management Inc. boosted its stake in shares of Eli Lilly and Company by 2.4% in the third quarter. Koshinski Asset Management Inc. now owns 4,785 shares of the company’s stock worth $3,651,000 after buying an additional 112 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Down 1.4%

LLY stock opened at $1,008.47 on Monday. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,133.95. The stock has a market cap of $951.35 billion, a price-to-earnings ratio of 43.94, a PEG ratio of 1.17 and a beta of 0.39. The business’s 50-day moving average is $1,054.83 and its 200 day moving average is $917.84.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. The business had revenue of $19.29 billion during the quarter, compared to analysts’ expectations of $17.85 billion. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The business’s revenue was up 42.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Friday, February 13th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s payout ratio is 30.15%.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Landmark long‑term Omvoh (mirikizumab) data — Phase 3 VIVID‑2 open‑label results showed >90% of Crohn’s patients who reached steroid‑free remission at one year remained steroid‑free at three years; low hospitalization and surgery rates reinforce Omvoh’s potential to reduce disease complications and extend market opportunity in IBD. Patients with Crohn’s disease maintained steroid-free remission for three years with Lilly’s Omvoh
• Positive Sentiment: Additional trial wins — Lilly reported another positive result for the Zepbound‑Taltz combination (psoriasis/obesity crossover strategy) and other pipeline progress that support revenue diversification beyond GLP‑1s. These clinical wins strengthen near‑ and medium‑term growth expectations. Lilly chalks up another trial win for Zepbound‑Taltz combo
• Positive Sentiment: Analyst support — Berenberg raised its price target from $950 to $1,050 while keeping a hold rating, signaling modest upside in analyst models that may buoy sentiment after recent gains. Berenberg adjusts price target on Eli Lilly
• Neutral Sentiment: Business development — Lilly entered a $100M licensing deal with CSL for clazakizumab, which diversifies partnerships and could add mid‑late‑stage value but is not immediately material to top‑line. Eli Lilly Enters $100 Million Licensing Agreement with CSL Limited
• Neutral Sentiment: New indications / trials — Lilly has launched/updated trials (e.g., brenipatide Phase 2 for opioid use disorder) that expand the pipeline but are early‑stage and carry typical clinical risk/reward. Eli Lilly pushes into opioid use disorder with new brenipatide Phase 2 trial
• Negative Sentiment: Valuation and GLP‑1 concentration risk — Commentary and analysis pieces flag that much of Lilly’s recent rally was driven by GLP‑1/weight‑loss momentum; competition and profitability normalization risks remain, which can prompt profit‑taking and cap further near‑term gains. Warning: This Skyrocketing Stock Has a Hidden Risk

Analyst Upgrades and Downgrades

LLY has been the subject of a number of analyst reports. Loop Capital set a $1,200.00 price target on Eli Lilly and Company in a report on Tuesday, February 10th. Cantor Fitzgerald boosted their target price on shares of Eli Lilly and Company from $985.00 to $1,205.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. UBS Group restated a “buy” rating on shares of Eli Lilly and Company in a research report on Monday, February 2nd. Wells Fargo & Company lifted their price objective on shares of Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. Finally, Guggenheim lowered their target price on shares of Eli Lilly and Company from $1,163.00 to $1,161.00 and set a “buy” rating on the stock in a research note on Tuesday, January 20th. Two analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $1,228.54.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.